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OBJECTIVES This study aimed to clarify the role of adenosine triphosphate-sensitive K (KATP) channels
in the no-reflow phenomenon and in its extension by hypercholesterolemia.
BACKGROUND The no-reflow phenomenon is an important target of therapy in patients with acute
myocardial infarction, but its mechanism remains unclear.
METHODS The left circumflex coronary artery was occluded for 30 or 60 min and reperfused in rabbit
hearts in situ. The no-reflow zone, area at risk, and infarct size were determined by
thioflavin-S, Evans blue, and tetrazolium staining, respectively. No-reflow zone size was
expressed as a percentage of infarct size (%NR/IS). Hypercholesterolemia was induced by two
weeks of cholesterol-enriched diet.
RESULTS A KATP channel blocker, glibenclamide (0.3 mg/kg), increased %NR/IS after 30-min
ischemia/90-min reperfusion from 33.6  1.9% to 45.9  1.6% and %NR/IS after 60-min
ischemia/90-min reperfusion from 32.8 3.4% to 46.1 1.7%. However, NG-monomethyl-
L-arginine (L-NMMA), a nitric oxide (NO) synthase inhibitor, and nicorandil, a hybrid of
KATP channel opener and nitrate, failed to significantly modify %NR/IS. Hypercholesterol-
emia increased %NR/IS to 61.6  0.6%, which was not further enlarged by glibenclamide,
and delayed infarct healing during the subsequent five days of reperfusion. These effects of
hypercholesterolemia were significantly suppressed by nicorandil. Neither glibenclamide,
L-NMMA, nicorandil, nor hypercholesterolemia modified infarct size.
CONCLUSIONS The KATP channel activation, but not NO, is a major mechanism of protection against
microvascular injury, causing the no-reflow phenomenon in the heart. Suppression of KATP
channel opening may underlie the hypercholesterolemia-induced extension of no-reflow,
which delays infarct healing. (J Am Coll Cardiol 2002;40:1339–46) © 2002 by the
American College of Cardiology Foundation
When a coronary artery has been occluded for a long period
of time, reopening of the artery fails to restore perfusion in
the entire ischemic myocardium and leaves some areas
without reperfusion (1–4). Even after recanalization of the
occluded coronary artery, the no-reflow phenomenon is
observed in 25% to 30% of patients (3,5). Furthermore, this
phenomenon has been shown to be associated with ventricular
remodeling and poor functional recovery after infarction (3,5–
7). Therefore, the no-reflow phenomenon appears to be an
important target of therapy, but the mechanism of this phe-
nomenon and methods for its prevention still remain elusive.
Although it has been suggested that plugging of capillar-
ies by leukocytes and platelet activation contribute to no-
reflow (1,2,8), these blood cell elements are not necessary
for the development of this phenomenon, because no-reflow
has been observed in buffer-perfused hearts as well (9,10). It
is not clear how ischemia induces irreversible damage in the
endothelium and vascular smooth muscle cells after ischemia/
reperfusion and whether there is any endogenous mecha-
nism against development of ischemic microvascular injury,
causing the no-reflow phenomenon.
In the present study, we examined the roles of adenosine
triphosphate-sensitive K (KATP) channels and nitric oxide
(NO) in the no-reflow phenomenon by using a KATP
channel blocker, an inhibitor of nitric oxide synthase
(NOS), and nicorandil, which is a hybrid drug of KATP
channel opener (11) and nitrate. In addition, we examined
the possibility that reported extension of the no-reflow zone
by hypercholesterolemia is due to suppressed function of the
KATP channel. Rationales for this hypothesis are previous
findings that chronic hypercholesterolemia impairs func-
tions of endothelial pertussis toxin-sensitive G proteins
(GPTX) (12) and that GPTX mediates a signal to the KATP
channel in coronary arterioles (13,14). However, to avoid the
influence of atherosclerosis on ischemic vascular injury, we
assessed the effects of a relatively short period (i.e., two weeks)
of hypercholesterolemia on the no-reflow phenomenon.
METHODS
This study was conducted in accordance with “The Guide
for the Care and Use of Laboratory Animals,” published by
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the National Institutes of Health (NIH publication No.
85-23, revised 1996) and was permitted by the Animal Use
Committee of Sapporo Medical University.
Experiment 1: Effects of KATP Channel Blockade and
Inhibition of NOS on the No-Reflow Phenomenon
Surgical preparation. Male albino rabbits (Japanese
White, 11 to 13 weeks old) were prepared to induce
myocardial infarction in vivo as in our previous studies
(15,16). In brief, rabbits were anesthetized with intravenous
(IV) pentobarbital (40 mg/kg), intubated, and ventilated by
a Harvard respirator (model 683, Harvard Apparatus, South
Natick, Massachusetts) using room air and oxygen supple-
ment. The heart was exposed, and a coronary snare was
placed around the marginal branch of the left coronary
artery. Fluid-filled catheters were placed in a carotid artery
and a jugular vein for monitoring of blood pressure and for
drug injection, respectively. An electrocardiogram was mon-
itored using precordial bipolar electrodes.
Experimental protocols. The left circumflex coronary ar-
tery of each rabbit was occluded for 30 min (30-min
ischemia protocol) or 60 min (60-min ischemia protocol)
and reperfused for 90 min. In both protocols, rabbits were
subjected to one of the following four pretreatments before
myocardial ischemia: 1) no pretreatment; 2) IV injection of
glibenclamide, a selective KATP channel blocker; 3) IV
injection of NG-monomethyl-L-arginine (L-NMMA), an
NOS inhibitor; and 4) infusion of nicorandil. Gliben-
clamide (0.3 mg/kg) was administered at 20 min before
coronary occlusion. The L-NMMA (30 mg/kg) was injected
5 min before ischemia and 5 min after reperfusion in the
30-min ischemia protocol and 5 min before and 35 min
after coronary occlusion and 5 min after reperfusion in the
60-min ischemia protocol. Nicorandil infusion (10 g/kg/
min IV) was commenced 5 min before ischemia and was
continued until the end of reperfusion. In pilot experiments,
this dose of L-NMMA inhibited hypotensive response (i.e.,
20 mm Hg of blood pressure fall) to 1 g/kg/min of
acetylcholine for at least 40 min. After 90 min of reperfu-
sion, the rabbits were heparinized with 2,000 U of heparin
sodium, and 1 ml/kg of 4% thioflavin-S in saline was
injected as a bolus to stain the vascular endothelium in vivo.
Postmortem analysis of the heart. After excision of the
heart, the circumflex artery was reoccluded to avoid wash-
out and diffusion of thioflavin-S from capillaries. The heart
was then mounted onto a Langendorff apparatus, and Evans
blue dye was infused into the perfusion line to negatively
mark the territory of the occluded artery (i.e., area at risk).
The heart was frozen and sectioned into six slices (each of
2-mm in thickness) from the apex to the base. Every other
slice was stained with triphenyltetrazolium chloride to
visualize infarcts (Fig. 1A) or illuminated with ultraviolet
light to determine the no-reflow zone (Fig. 1B), but the
areas of infarct, risk zone, and no-reflow zone in the same
cross sections could be measured by tracing those areas on
the facing aspects of two adjacent slices. The trace images of
these areas were read by a Macintosh G3 computer and
measured using NIH image, an image analysis software. To
confirm no-reflow zone assessment by thioflavin-S, histol-
ogy slides were prepared from the slices used for no-reflow
analysis and stained with hematoxylin-eosin.
Experiment 2: Effects of Hypercholesterolemia on the
No-Reflow Phenomenon
Preparation of hypercholesterolemic rabbits and their
controls. Eleven-week-old rabbits were fed a 1%
cholesterol-enriched diet (Oriental Yeast Co., Tokyo, Ja-
pan) or a standard laboratory chow for two weeks before the
experiment. Rabbits were prepared as in Experiment 1, and
blood samples were taken on the day of the experiment for
measurements of plasma total cholesterol (TC), low density
lipoprotein cholesterol (LDL-C), and triglyceride (TG) by
enzymatic assay.
Experimental protocol. After a 15-min stabilization pe-
riod, all rabbits underwent 30-min coronary occlusion and
90-min reperfusion. Rabbits that were fed a standard chow
received no pretreatment and served as controls. Hypercho-
lesterolemic rabbits received injection of saline (vehicle) or
one of the following three treatments: glibenclamide injec-
tion, nicorandil infusion, and nitroglycerin infusion. Glib-
Abbreviations and Acronyms
ANOVA  analysis of variance
GPTX  pertussis toxin-sensitive G protein
%IS/AR  infarct size as a percentage of area at
risk
IV  intravenous
KATP channel  adenosine triphosphate-sensitive K

channel
KCa channel  Ca
2-activated K channel
LDL-C  low density lipoprotein-cholesterol
L-NMMA  NG-monomethyl-L-arginine
NO  nitric oxide
NOS  nitric oxide synthase
%NR/IS  no-reflow zone size as a percentage of
infarct size
%OZ/IS  volume of organized infarct as a
percentage of whole infarct size
TC  total cholesterol
TG  triglycerides
Figure 1. A representative example of a heart after 30-min coronary
occlusion and 90-min reperfusion. (A) Triphenyltetrazolium chloride
stained the noninfarcted region red, and the infarcted region remained
unstained. The nonischemic region was stained by Evans blue dye. (B)
Under ultraviolet light, the no-reflow zone was identified as a region
deficient in fluorescence of thioflavin-S.
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enclamide (0.3 mg/kg) was intravenously injected at 20 min
before coronary occlusion. Nicorandil (10 g/kg/min) in-
fusion and nitroglycerin (1 g/kg/min) infusion were com-
menced at 5 min before ischemia and continued until the
end of reperfusion. Determination of no-reflow zone size
and risk zone size was performed as in Experiment 1. Using
separate groups of hypercholesterolemic and normocholes-
terolemic rabbits (n  4 for each group), ventricular muscle
samples without ischemia were excised and quickly frozen in
liquid nitrogen. The protein levels of SUR2, Kir6.1, and
Kir6.2 in the tissue samples were assessed by Western
blotting.
Western blotting of SUR2, Kir6.1, and Kir6.2.
Ventricular tissue samples were homogenized, and particu-
late fractions were separated from cytosolic fractions and
processed for Western blotting as previously reported (17).
In brief, the particulate samples were electrophoresed on a
12.5% polyacrylamide gel and then electroblotted onto
polyvinylidine difluoride membranes (Millipore, Bedford,
Massachusetts). After blocking with buffer containing 5%
nonfat dry milk, the blots were then incubated with 1,000-
fold diluted antibodies against SUR2, Kir6.1, and Kir6.2
(Santa Cruz Biotechnology, Santa Cruz, California). These
proteins were then visualized using secondary antibodies
and an ECL Western blotting detection kit (Amersham,
Little Chalfont, Minnesota). Protein levels of SUR2,
Kir6.1, and Kir6.2 were quantified by using SigmaGel, gel
analysis software (SPSS Inc., Chicago, Illinois).
Experiment 3: Effects of KATP Channel Blockade and
Hypercholesterolemia on Infarct Healing
Surgical preparation and experimental protocols. Be-
cause a KATP channel blocker and hypercholesterolemia
enlarged no-reflow zone size (see Results section), the
impact of such extension of the no-reflow zone on infarct
healing was examined in these experiments. Rabbits with
hypercholesterolemia and normal controls were prepared as
in Experiments 1 and 2. All rabbits underwent 60-min
coronary occlusion and reperfusion. Normal control rabbits
received injection of saline or glibenclamide (0.3 mg/kg) at 20
min before coronary occlusion. Hypercholesterolemic rabbits
received saline or nicorandil infusion (10 g/kg/min) from 5
min before ischemia until 90 min after reperfusion.
After stabilization of hemodynamic parameters following
reperfusion, the surgical wounds were repaired, and rabbits
were returned to their cages for recovery. At five days after
the surgery, rabbits were heparinized and hearts were then
excised and processed for postmortem analysis. In these
experiments, surgical procedures were performed under
sterile conditions, and a combination of 100 mg ampicillin
and 100 mg cloxacillin was injected intramuscularly for
prophylaxis of infection. After the surgery, all rabbits were
fed a standard chow.
Postmortem analysis. Excised hearts were immersion-
fixed in 10% neutrally buffered formalin for at least two days
and sectioned into 2.5-mm-thick slices. Histology slides
were prepared from each heart slice by standard techniques
and stained with hematoxylin-eosin and Mallory’s connec-
tive tissue stain modified by Heidenhaim. The slide images
were enlarged 9.2 times using a CanoScan 600 scanner
(Canon, Tokyo, Japan) and a Macintosh G3 computer.
Infarcted zone and the organized zone (i.e., granulation
tissue and fibrosis) of the infarct (Fig. 2) were traced and
their areas were determined by NIH image. Based on our
previous studies (15,16), we used the volume of organized
infarct as a percentage of whole infarct size (%OZ/IS) as an
index to assess the extent of infarct healing. Because
%OZ/IS inversely correlates with absolute volume of infarct
(indicating that infarct healing is slower in larger infarcts),
delay of infarct healing was assessed as a shift of infarct
size-%OZ/IS relationship. The validity of this approach for
determining the effects of reperfusion and corticosteroids on
the rate of infarct healing has been demonstrated (15,16).
Chemicals. Glibenclamide, L-NMMA, and thioflavin-S
were purchased from Sigma (St. Louis, Missouri). Nitro-
glycerin was obtained from Nihon Kayaku Co. (Tokyo,
Japan). Nicorandil was provided by Chugai Pharmaceutical
(Tokyo, Japan).
Statistical analysis. One-way analysis of variance
(ANOVA) combined with the Scheffe´ post hoc test was
used to assay intergroup differences. Differences between
time-related hemodynamic parameters in treatment groups
were tested by two-way repeated-measures ANOVA. Dif-
ferences in regression lines were compared using analysis of
covariance. The difference was considered significant at a
level of p  0.05. SigmaStat (SPSS Inc.) was used to
perform ANOVA. All data are presented as means SEM.
RESULTS
Experiment 1
Mortality and hemodynamic parameters. A total of 54
rabbits were used in Experiment 1, and none of them died
during the coronary occlusion and reperfusion. As shown in
Table 1, baseline heart rate and mean blood pressure were
comparable among the groups. Administration of
L-NMMA slightly increased mean blood pressure and
decreased heart rate, but these differences did not reach
statistical significance. After ischemia/reperfusion, mean
blood pressure was decreased in all groups without any
significant intergroup differences.
Effects of glibenclamide, L-NMMA, and nicorandil on
no-reflow zone size. As shown in Table 1, 60-min isch-
emia resulted in larger infarcts than did 30-min ischemia in
the controls: infarct sizes as a percentage of area at risk
(%IS/AR) were 89.3  1.4% and 49.0  4.6%, respectively
(p  0.05). However, sizes of the no-reflow zone as a
percentage of infarct size (%NR/IS) were similar after
30-min and 60-min coronary occlusion (33.6  1.9% vs.
32.8  3.4%). There was also no difference between
histological findings of the no-reflow zone (i.e., plugging of
capillaries with red cells, interstitial hemorrhage, and
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contraction-band necrosis of myocytes) in the 30-min isch-
emia and 60-min ischemia protocols. The %IS/AR was not
modified by glibenclamide, L-NMMA, or nicorandil. How-
ever, glibenclamide increased %NR/IS after 30-min isch-
emia and after 60-min ischemia by approximately 1.5-fold
to 45.9  1.6% and 46.1  1.7%, respectively (p  0.05 vs.
controls). The L-NMMA treatment tended to increase
%NR/IS after 30-min and 60-min ischemia, but the differ-
ences from untreated controls did not reach a statistical
significance. Nicorandil failed to reduce %NR/IS in both
30-min ischemia and 60-min ischemia protocols.
Experiment 2
Effects of cholesterol-enriched diet on plasma lipid pro-
file. Levels of plasma TC and LDL-C were significantly
higher in the rabbits fed a cholesterol-enriched diet than in
the control rabbits (641  48 vs. 36  2 mg/dl, 364  31
vs. 12  1 mg/dl), whereas plasma TG level tended to be
Figure 2. An example of the histology slide in a rabbit heart that received 60-min coronary occlusion and five days of reperfusion. The infarcted region
consisted of central core of coagulation necrosis (C) and an organized zone (i.e., granulation tissue [G]) surrounding the core of necrosis (hematoxylin-eosin
staining). The organized zone (G) and total infarct area (i.e., G plus C) were measured by NIH image, and the volume of the organized zone expressed
as a percentage of total infarct size was calculated for each heart as an index of the extent of infarct healing. N  noninfarcted myocardium.
Table 1. Hemodynamic Parameters, Infarct Size, and No-Reflow Zone Size in Experiment 1
Treatment n






Zone (cm3) %IS/AR %NR/ISBaseline Ischemia Baseline Ischemia
30-min ischemia protocol
Control 8 295  9 301  8 100  2 95  3 0.83  0.13 0.44  0.10 0.15  0.04 49.0  4.6 33.6  1.9
Glibenclamide 8 287  12 294  24 98  1 91  3* 0.83  0.06 0.46  0.06 0.21  0.03 55.2  4.4 45.9  1.6†
L-NMMA 8 282  9 270  8 97  1 98  2 0.78  0.12 0.36  0.09 0.14  0.03 43.2  4.4 42.2  3.8
Nicorandil 6 318  17 300  17 99  3 89  5* 0.72  0.10 0.35  0.05 0.13  0.02 48.9  3.2 35.6  1.3
60-min ischemia protocol
Control 8 281  9 281  8 95  2 93  2 0.62  0.08 0.56  0.08 0.18  0.03 89.3  1.4 32.8  3.4
Glibenclamide 6 298  17 282  10 94  2 90  5 0.67  0.15 0.61  0.14 0.29  0.08 90.5  1.3 46.1  1.7†
L-NMMA 5 280  12 262  11 94  2 90  5 0.66  0.14 0.60  0.14 0.25  0.06 89.8  2.3 40.8  1.0
Nicorandil 5 280  5 279  4 93  3 87  2 0.66  0.11 0.62  0.10 0.21  0.05 92.7  1.7 33.5  5.2
Mean  SEM. *p  0.05 vs. Baseline. †p  0.05 vs. Control group.
BP  blood pressure; %IS/AR  infarct size as % of area at risk; L-NMMA  NG-monomethyl-L-arginine; %NR/IS  no-reflow zone size as % of infarct size.
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lower in the hypercholesterolemic rabbits than in the
controls (46.1 13.1 vs. 81.0 14.5 mg/dl). No significant
differences existed between plasma lipid profiles in hyper-
cholesterolemic rabbits that received nicorandil, nitroglyc-
erin, or glibenclamide and those that received no drug
treatment (data not shown).
Mortality and hemodynamic parameters. Thirty-six rab-
bits were used in this series of experiments, and 8 rabbits (1
normal control, 3 hypercholesterolemic controls, 2 hyper-
cholesterolemic rabbits that received nicorandil infusion and
2 hypercholesterolemic rabbits that received nitroglycerin)
died from ventricular fibrillation during the coronary occlu-
sion. At baseline, mean blood pressure was comparable
among the groups, as shown in Table 2. Infusion of
nicorandil and nitroglycerin tended to reduce mean blood
pressure by a few mm Hg, but the changes were not
statistically significant. After coronary occlusion and reper-
fusion, mean blood pressure was decreased in all groups
without any significant intergroup differences. Heart rates
were comparable in the study groups throughout the exper-
iments.
Effects of hypercholesterolemia on no-reflow zone
size. The sizes of the risk area were comparable among the
study groups, and both %IS/AR and %NR/IS in normal
controls were similar to those in Experiment 1. In hyper-
cholesterolemia controls, %NR/IS was almost two-fold
larger than that in the normal controls (61.6  0.6% vs.
33.7  4.2%, p  0.05), while there was no significant
difference between infarct sizes in these groups (Table 2).
Administration of glibenclamide did not induce additional
enlargement of the no-reflow zone in hypercholesterolemic
rabbits (%NR/IS  67.4  3.3%). Nicorandil infusion,
but not nitroglycerin infusion, significantly reduced the
no-reflow zone size in hypercholesterolemic rabbits
(%NR/IS  46.5  3.7%, 60.9  1.6%, respectively). No
significant difference was seen between infarct sizes in all
treatment groups (Table 2).
Western blotting of SUR2, Kir6.1, Kir6.2. The densito-
metric analysis showed that SUR, Kir6.1, and Kir6.2 levels
were slightly higher in hypercholesterolemic rabbits than in
normal rabbits (919  63 arbitrary units [au] vs. 897  103
[au], 879  77 [au] vs. 694  56 [au], and 1,330  34 [au]
vs. 1,108  58 [au]), though only the difference between
Kir6.2 levels was statistically significant.
Experiment 3
Mortality and hemodynamic parameters. Of the 34 rab-
bits used in Experiment 3, one rabbit in each study group
died after the surgery, presumably due to heart failure after
myocardial infarction. Alterations of hemodynamic param-
eters by ischemia/reperfusion in Experiment 3 were similar
to those in Experiments 1 and 2 (data not shown).
Relationship between infarct size and extent of infarct
healing. As previously reported (15,16), %OZ/IS was in-
versely correlated with infarct size in all study groups,
indicating that larger infarcts healed more slowly (Fig. 3).
However, slopes of the regression lines in hypercholester-
olemic rabbits and glibenclamide-treated rabbits were more
negative compared with those in the controls, though the
difference between the glibenclamide-treated and control
rabbits was not statistically significant. Administration of
nicorandil in hypercholesterolemic rabbits significantly
shifted the regression line upward compared with that for
hypercholesterolemia controls. These findings suggest that
infarct healing was delayed by hypercholesterolemia and
possibly by glibenclamide and that nicorandil prevented
hypercholesterolemia-induced delay in the infarct healing
process.
DISCUSSION
Roles of the KATP channel and NO in the no-reflow
phenomenon. Nitric oxide and the KATP channel are
important regulators of coronary circulation, though NO
dilates mainly larger arterioles and the KATP channel dilates
smaller arterioles (14,18). In the present study, gliben-
clamide, a blocker of the KATP channel, enlarged the
no-reflow zone by 40%, and this effect was observed after
30 min and also after 60 min of ischemia, resulting in
different sizes of infarct. The no-reflow zone sizes in
L-NMMA-treated rabbits tended to be enlarged, but dif-
ferences between untreated controls and L-NMMA-treated
groups were not statistically significant in either the 30-min
or 60-min ischemia protocol. These findings suggest that
activation of the KATP channel plays a major role in
protection of the microvasculature from irreversible damage
during ischemia/reperfusion, while the possibility of some
contribution of NO cannot be excluded. Furthermore, levels
of KATP channel activation and NO production during
Table 2. Hemodynamic Parameters, Infarct Size, and No-Reflow Zone Size in Experiment 2
Treatment n






Zone (cm3) %IS/AR %NR/ISBaseline Ischemia Baseline Ischemia
Control 5 286  10 276  8 91  3 93  5 0.63  0.09 0.28  0.04 0.10  0.02 44.3  3.9 33.7  4.2
Hyperchol 5 323  15 311  18 110  3 100  6 0.67  0.14 0.33  0.07 0.21  0.05 51.9  3.8 61.6  0.6*
Hyperchol/glib 6 275  19 282  21 102  4 95  3 0.68  0.07 0.38  0.05 0.26  0.04 55.0  2.5 67.4  3.3*
Hyperchol/nicorandil 6 313  13 298  7 108  6 98  4 0.64  0.07 0.31  0.05 0.15  0.03 48.5  5.4 46.5  3.7†
Hyperchol/TNG 6 298  12 274  7 98  5 92  5 0.73  0.10 0.40  0.10 0.25  0.07 50.0  6.6 60.9  1.6*
Mean  SEM. *p  0.05 vs. Control group. †p  0.05 vs. Hyperchol, Hyperchol/glib, and Hyperchol/TNG group.
BP  blood pressure; glib  glibenclamide; Hyperchol  hypercholesterolemia; %IS/AR  infarct size as % of area at risk; %NR/IS  no-reflow zone size as % of infarct
size; TNG  nitroglycerin.
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ischemia/reperfusion in normal rabbits appear to be above
their thresholds for protection, because administration of
nicorandil, a hybrid of KATP channel opener and nitrate,
failed to modify the no-reflow zone size. It is also notable
that this protective effect by endogenous activation of the
KATP channel is likely to be specific to the microvasculature,
as myocardial infarct size was not enlarged by gliben-
clamide.
In the present study, we selected 90 min after reperfusion
as the time point for no-reflow zone determination; this is
because we previously found that the size of the no-reflow
zone in the same rabbit model of infarction increased
threefold from 10 to 60 min after reperfusion (2). We
cannot exclude the possibility that the size of the no-reflow
zone increases further after this time point. However,
intergroup differences in no-reflow zone size at 90 min after
reperfusion inversely correlated with those in %OZ/IS,
which was measured 5 days after reperfusion. These findings
suggest that alterations in no-reflow zone size at 90 min
after reperfusion indeed reflect the changes in ultimate size
of the no-reflow zone in our rabbit preparation.
Effects of hypercholesterolemia on the no-reflow phe-
nomenon. Extension of the no-reflow zone size by hyper-
cholesterolemia in the present study was consistent with an
earlier observation by Golino et al. (19,20), who fed rabbits
a cholesterol-enriched diet for three days and induced
infarction by 30-min coronary occlusion. We hypothesized
that impairment of KATP channel function during ischemia/
reperfusion is an important mechanism for extension of
no-reflow by hypercholesterolemia. This hypothesis was
supported by two lines of evidence in the present experi-
ments. First, a KATP channel blocker, glibenclamide,
did not further enlarge the no-reflow zone in hyper-
cholesterolemic rabbits, in contrast with its effect in rabbits
with normal cholesterol levels. Second, nicorandil, a hybrid
of KATP opener and nitrate, significantly blunted
hypercholesterolemia-induced extension of no-reflow, but
this effect was not mimicked by a nitrate donor, nitroglyc-
erin.
How hypercholesterolemia impaired KATP channel func-
tion in the microvasculature during ischemia/reperfusion
remains unclear. The SUR2, Kir6.1, and Kir6.2 levels were
not reduced in the hypercholesterolemic rabbits in the
present study. Although we could not selectively assess the
protein level of smooth muscle type SUR2 (i.e., SUR2B),
these results argue against the possibility that hypercholes-
terolemia reduces expression of vascular KATP channels.
Conversely, recent studies have provided circumstantial
evidence of the involvement of G protein dysfunction in
altered function of the KATP channel induced by hypercho-
lesterolemia (12–14,21). The GPTX protein plays an impor-
tant role in regulation of KATP channels (13,14), and its
function is impaired by chronic hypercholesterolemia (12).
A recent study by Pongo et al. (21) demonstrated dysfunc-
tion in protein kinase C–KATP channel coupling by hyper-
cholesterolemia in rabbit coronary arteries. Furthermore,
this hypercholesterol-induced impairment was restored by
treatment with farnesol, suggesting that failed association of
G protein with the membrane may underlie the disturbance
in signal-mediated regulation of the KATP channel. Never-
Figure 3. Relationship between infarct size and organized infarct volume expressed as a percentage of the entire infarct (%OZ/IS) five days after infarction.
Control  untreated controls; Glibenclamide  normal rabbits treated with glibenclamide; Hyperchol  hypercholesterolemic rabbits; Hyperchol/
nicorandil  hypercholesterolemic rabbits treated with nicorandil. The %OZ/IS was inversely correlated with infarct size in all study groups. However, the
slope of the regression line in the hypercholesterolemic group (open circles; y  27.8x  100.8, r  0.96) was significantly more negative than that in
the untreated control group (open squares; y  9.5x  96.3, r  0.73). The slope of the regression line in the glibenclamide-treated group (open
triangles; y18.3x 101.2, r 0.96) was also more negative than that in the untreated controls, but the difference did not reach statistical significance.
The regression line in the nicorandil-treated hypercholesterolemic group (closed circles; y  26.7x  109.4, r  0.64) was significantly shifted upward
compared with that in the hypercholesterolemic group.
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theless, further investigation is needed to clarify the mech-
anism by which hypercholesterolemia inhibits function of
the KATP channel during myocardial ischemia/reperfusion.
Infusion of nicorandil prevented 55% of the extension of
the no-reflow zone induced by hypercholesterolemia. We
did not use large doses of nicorandil to minimize its effects
on systemic hemodynamics, and we cannot exclude the
possibility that a high dose may be necessary to totally
prevent the effect of hypercholesterolemia. However, other
mechanisms such as hypersensitivity of platelets and dys-
function of the Ca2-activated K (KCa) channel may also
contribute to aggravation of the no-reflow phenomenon by
hypercholesterolemia (20,22,23). Golino et al. (20) reported
that depletion of platelets by anti-platelet serum prevented
enlargement of the no-reflow zone size and infarct size by
hypercholesterolemia. A recent study by Jeremy and Mc-
Carron (22) demonstrated that hypercholesterolemia im-
paired KCa-mediated vasodilation in systemic arteries in
rabbits. Such a KCa channel dysfunction in the coronary
arteries, if any, would accelerate ischemia-induced injury of
microvessels, because the KCa channel plays a critical role in
coronary vasodilation under the condition of hypoperfusion
(23).
Effect of the no-reflow phenomenon on infarct healing.
An earlier study from this laboratory (15) demonstrated that
reperfusion after myocardial infarction substantially acceler-
ates replacement of necrotic myocytes with granulation
tissues, even when reperfusion was too late to salvage the
myocardium. Because the no-reflow phenomenon compro-
mises reperfusion of the infarcted myocardium, it should
offset the reperfusion-induced acceleration of infarct heal-
ing. Owing to methodological limitation, we could not
measure no-reflow zone and extent of infarct healing in the
same animal. However, enlargement of the no-reflow zone
size by glibenclamide and hypercholesterolemia and its
reversal by nicorandil corresponded to their effects on the
extent of infarct healing (Table 2, Fig. 3). Effects of
glibenclamide on no-reflow zone size and %OZ/IS were
modest compared with those of hypercholesterolemia. Fur-
thermore, the effects of hypercholesterolemia on both no-
reflow zone size and %OZ/IS were significantly attenuated
by nicorandil. These findings strongly support the notion
that the no-reflow phenomenon delays the healing process
of infarcts.
Possible clinical implications. Clinical studies (6,24) have
shown that reduction in no-reflow zone size suppressed
subsequent ventricular remodeling and dysfunction a month
later. However, earlier studies (1,2,25) and the present
experiments (Table 2) have failed to demonstrate that
suppression of no-reflow results in infarct size limitation. A
possible explanation for this apparent discrepancy is that a
clinical benefit of suppression of no-reflow may be acceler-
ation of infarct repair, which would prevent expansion of the
infarcted region and possibly preserve the contractile func-
tion of the salvaged subepicardial myocardium.
In contrast with the present rabbit experiments, hyper-
cholesterolemia is unlikely to be a requisite for beneficial
effects of nicorandil on no-reflow in human hearts (6). A
plausible explanation for this difference is that the coronary
microvasculature in humans, particularly in patients with
coronary artery disease, may be vulnerable to ischemia/
reperfusion injury. In fact, coronary endothelial dysfunction
has been demonstrated in patients with coronary artery
disease (26), though alteration in vascular smooth muscles
has not been fully characterized (27).
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